----

**UNITED        STATES**

**SECURITIES        AND EXCHANGE COMMISSION**

**WASHINGTON,        DC 20549**

**FORM        10-Q**

| **x** | **QUARTERLY                  REPORT PURSUANT TO                  SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                  1934** |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------|

| ** ̈** | **TRANSITION                  REPORT PURSUANT TO                  SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                  1934** |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

**DENDREON        CORPORATION**

**(Exact        name of registrant as specified in its charter)**

|                                                                                                 |                                                   |
|------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| **DELAWARE**                                                                                         | **22-3203193**                                         |
| **(State                  or other jurisdiction of incorporation or                  organization)** | **(IRS                  Employer Identification No.)** |
|                                                                                                 |                                                   |
| **3005                  FIRST AVENUE,****SEATTLE,                  WASHINGTON**                      | **98121**                                              |
| **(Address                  of registrant’s principal executive offices)**                     | **(Zip                  Code)**                        |

**(206)        256-4545**

**(Registrant’s        telephone number, including area code)**

----

**DENDREON        CORPORATION**

**INDEX**

|                                                                                                         |                                                                                                                                                                  | **PAGE NO.** |
|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
|                                                                                                         |                                                                                                                                                                  |              |
| **PART                    I. FINANCIAL INFORMATION**                                                         |                                                                                                                                                                  |
|                                                                                                         |                                                                                                                                                                  |              |
| Item 1.                                                                                                 | Financial                    Statements                                                                                                                               |  3           |
|                                                                                                         |                                                                                                                                                                  |              |
|                                                                                                         | Consolidated                    Balance Sheets as of September                    30, 2007 and December 31, 2006                                                      |  3           |
|                                                                                                         |                                                                                                                                                                  |              |
|                                                                                                         | Consolidated                    Statements of Operations for the                    Three Months and Nine Months Ended September 30, 2007 and                    2006 |  4           |
|                                                                                                         |                                                                                                                                                                  |              |
|                                                                                                         | Consolidated                    Statements of Cash Flows for the Nine                    Months Ended September 30, 2007 and 2006                                     |  5           |
|                                                                                                         |                                                                                                                                                                  |              |
|                                                                                                         | Notes                    to Consolidated Financial                    Statements                                                                                      |  6           |
|                                                                                                         |                                                                                                                                                                  |              |
| Item 2.                                                                                                 | Management’s                    Discussion and Analysis of Financial Condition                    and Results of Operations                                     |  13          |
|                                                                                                         |                                                                                                                                                                  |              |
| Item 3.                                                                                                 | Quantitative                    and Qualitative Disclosures About Market                    Risk                                                                      |  19          |
|                                                                                                         |                                                                                                                                                                  |              |
| Item 4.                                                                                                 | Controls                    and Procedures                                                                                                                            |  20          |
|                                                                                                         |                                                                                                                                                                  |              |
| **PART                    II. OTHER INFORMATION**                                                            |                                                                                                                                                                  |
|                                                                                                         |                                                                                                                                                                  |              |
| Item                    1.                                                                                   | Legal                    Proceedings                                                                                                                                  |  20          |
|                                                                                                         |                                                                                                                                                                  |              |
| Item                    5.                                                                                   | Other                    Information                                                                                                                                  |  21          |
|                                                                                                         |                                                                                                                                                                  |              |
| Item 6.                                                                                                 | Exhibits                                                                                                                                                              |  22          |
|                                                                                                         |                                                                                                                                                                  |              |
| SIGNATURES                                                                                                   |  23                                                                                                                                                              |
|                                                                                                         |                                                                                                                                                                  |              |
| EXHIBIT                    INDEX                                                                             |  24                                                                                                                                                              |
| CERTIFICATION                    OF CEO PURSUANT TO SECTION 302 OF                    SARBANES OXLEY         |                                                                                                                                                                  |
| CERTIFICATION                    OF CFO PURSUANT TO SECTION 302 OF                    SARBANES OXLEY         |                                                                                                                                                                  |
| CERTIFIACTION                    OF CEO AND CFO PURSUANT TO SECTION 906                    OF SARBANES OXLEY |                                                                                                                                                                  |

----

**PART        I. FINANCIAL INFORMATION**

| **ITEM 1.** | **FINANCIAL                  STATEMENTS** |
|------------------|-------------------------------------------|

**DENDREON        CORPORATION**

**CONSOLIDATED        BALANCE SHEETS**

**(In        thousands, except share data)**

|                                                                                                                                                                                                                                                                                            | **September                    30,**                                                                          |     | **December ****31,**                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------|
| **2007**                                                                                                                                                                                                                                                                                        |                                                                                                          | **2006** |
|                                                                                                                                                                                                                                                                                            | **(unaudited)**                                                                                               |     |                                                                                                                                    |
| **ASSETS**                                                                                                                                                                                                                                                                                      |                                                                                                          |     |                                                                                                                                    |
| Current                    assets:                                                                                                                                                                                                                                                              |                                                                                                          |     |                                                                                                                                    |
| Cash                    and cash equivalents                                                                                                                                                                                                                                                    | $                              90,950                       |     | $            60,964                                                         |
| Short-term                    investments                                                                                                                                                                                                                                                       | 30,184                                                                                                        |     | 45,492                                                                                                                                  |
| Restricted                    cash                                                                                                                                                                                                                                                              | 1,858                                                                                                         |     | 1,440                                                                                                                                   |
| Prepaid                    and other current assets                                                                                                                                                                                                                                             | 2,087                                                                                                         |     | 2,082                                                                                                                                   |
| Total                    current assets                                                                                                                                                                                                                                                         | 125,079                                                                                                       |     | 109,978                                                                                                                                 |
| Property                    and equipment, net                                                                                                                                                                                                                                                  | 28,175                                                                                                        |     | 30,530                                                                                                                                  |
| Long-term                    investments                                                                                                                                                                                                                                                        | 17,694                                                                                                        |     | 14,827                                                                                                                                  |
| Long-term                    restricted cash                                                                                                                                                                                                                                                    | 6,657                                                                                                         |     | 7,723                                                                                                                                   |
| Debt                    issuance costs and other assets                                                                                                                                                                                                                                         | 3,454                                                                                                         |     | 585                                                                                                                                     |
| Total                    assets                                                                                                                                                                                                                                                                 | $         181,059                                                |     | $                             163,643                                                                |
| **LIABILITIES                    AND STOCKHOLDERS’ EQUITY**                                                                                                                                                                                                                               |                                                                                                          |     |                                                                                                                                    |
| Current                    liabilities:                                                                                                                                                                                                                                                         |                                                                                                          |     |                                                                                                                                    |
| Accounts                    payable                                                                                                                                                                                                                                                             | $                                   434 |     | $                                1,503                                      |
| Accrued                    liabilities                                                                                                                                                                                                                                                          | 7,347                                                                                                         |     | 6,788                                                                                                                                   |
| Accrued                    compensation                                                                                                                                                                                                                                                         | 4,037                                                                                                         |     | 5,312                                                                                                                                   |
| Deferred                    revenue                                                                                                                                                                                                                                                             | 82                                                                                                            |     | 95                                                                                                                                      |
| Current                    portion of capital lease obligations                                                                                                                                                                                                                                 |   967                                                                                               |     | 1,253                                                                                                                                   |
| Current                    portion of long-term debt and facility lease obligation                                                                                                                                                                                                              | 5,874                                                                                                         |     | 5,470                                                                                                                                   |
| Total                    current liabilities                                                                                                                                                                                                                                                    | 18,741                                                                                                        |     | 20,421                                                                                                                                  |
| Deferred                    revenue, less current portion                                                                                                                                                                                                                                       | 417                                                                                                           |     | 478                                                                                                                                     |
| Capital                    lease obligations, less current portion                                                                                                                                                                                                                              | 170                                                                                                           |     | 735                                                                                                                                     |
| Long-term                    debt, less current portion                                                                                                                                                                                                                                         | 3,581                                                                                                         |     | 7,879                                                                                                                                   |
| Facility                    lease obligation, less current portion                                                                                                                                                                                                                              | 8,289                                                                                                         |     | 8,413                                                                                                                                   |
| Convertible                    notes                                                                                                                                                                                                                                                            | 85,250                                                                                                        |     |                                     —   |
| Commitments                    and contingencies (Note 7)                                                                                                                                                                                                                                       |                                                                                                          |     |                                                                                                                                    |
| Stockholders’                    equity:                                                                                                                                                                                                                                                  |                                                                                                          |     |                                                                                                                                    |
| Preferred                    stock, $0.001 par value; 10,000,000 shares authorized, no shares                    issued or                    outstanding                                                                                                                                       |                —             |     |                  —                 |
| Common                    stock, $0.001 par value; 150,000,000 shares authorized, 83,013,907                    and                    81,323,628 shares issued and  outstanding                    at September 30, 2007 and December 31, 2006,                    respectively | 83                                                                                                            |     | 81                                                                                                                                      |
| Additional                    paid-in capital                                                                                                                                                                                                                                                   | 529,267                                                                                                       |     | 518,127                                                                                                                                 |
| Accumulated                    other comprehensive loss                                                                                                                                                                                                                                         | (41)                                                                                                          |     | (106)                                                                                                                                   |
| Accumulated                    deficit                                                                                                                                                                                                                                                          | (464,698)                                                                                                     |     | (392,385)                                                                                                                               |
| Total                    stockholders’ equity                                                                                                                                                                                                                                             |                      64,611                                                                              |     | 125,717                                                                                                                                 |
| Total                    liabilities and stockholders’ equity                                                                                                                                                                                                                             | $         181,059                                                |     | $          163,643                                                                    |
|                                                                                                                                                                                                                                                                                            |                                                                                                          |     |                                                                                                                                    |

----

**DENDREON        CORPORATION**

**CONSOLIDATEDSTATEMENTS        OF        OPERATIONS**

**(In        thousands, except per share amounts)**

**(unaudited)**

|                                                                                                 | **Three                  Months Ended**                                                                    |                               | **Nine                  Months Ended**                                                                           |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------|------------------------------------------------------------------------------------------------------------------|
| **September                  30,**                                                                   |                                                                                                       | **September                  30,** |
|                                                                                                 | **2007**                                                                                                   |                               | **2006**                                                                                                         |   | **2007** |   | **2006** |
| Revenue                                                                                              | $                                112 |                               | $                                  84 |   | $                             715 |   | $                                                 187 |
| Operating                  expenses:                                                                 |                                                                                                       |                               |                                                                                                             |   |   |   |   |
| Research                  and development                                                            | 13,449                                                                                                     |                               | 15,754                                                                                                           |   |         54,780 |   | 56,995 |
| General                  and administrative                                                          | 6,364                                                                                                      |                               | 5,974                                                                                                            |   | 20,458 |   | 16,634 |
| Total                  operating expenses                                                            | 19,813                                                                                                     |                               |  21,728                                                                                                     |   | 75,238 |   | 73,629 |
| Loss                  from operations                                                                |       (19,701)                                                               |                               |       (21,644)                                                                     |   |       (74,523) |   |       (73,442) |
| Interest                  income                                                                     |               2,022                  |                               |               1,353                        |   | 4,744 |   | 4,641 |
| Interest                  expense                                                                    |  (1,551)                                                                                              |                               |  (452)                                                                                                      |   |  (2,534) |   |  (1,354) |
| Net                  loss                                                                            | $                        (19,230)                                                 |                               | $                        (20,743)                                                  |   | $    (72,313) |   | $       (70,155) |
| Basic                  and diluted net loss per share                                                | $                            (0.23)                      |                               | $                            (0.29)                            |   | $        (0.88) |   | $           (0.98) |
| Shares                  used in computation of basic and diluted net loss per                  share |  82,965                                                                                               |                               |  71,320                                                                                                     |   |  82,356 |   |  71,236 |

----

**DENDREON        CORPORATION**

**CONSOLIDATED        STATEMENTS OF CASH FLOWS**

**(In        thousands)**

**(unaudited)**

|                                                                                                              | **Nine                    Months Ended**                                                          |
|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
|                                                                                                              | **September                    30,**                                                              |
|                                                                                                              | **2007**                                                                                          |   | **200** |
|     Operating                    Activities:                                                  |                                                                                              |   |   |
| Net                    loss                                                                                       | $     (72,313)                                                           |   | $                        (70,155) |
| Adjustments                    to reconcile net loss to net cash used in operating                    activities: |                                                                                              |   |   |
| Depreciation                    and amortization expense                                                          | 4,719                                                                                             |   | 2,784 |
| Non-cash                    stock-based compensation expense                                                      | 4,149                                                                                             |   | 2,966 |
| Net                    loss (gain) on sale of fixed assets                                                        | 42                                                                                                |   | (15) |
| Impairment                    of fixed assets                                                                     |                — |   | 419 |
| Changes                    in operating assets and liabilities:                                                   |                                                                                              |   |   |
| Accounts                    receivable                                                                            |                — |   |  (308) |
| Prepaid                    expenses and other assets                                                              |                119     |   |   363 |
| Deferred                    revenue                                                                               |  (74)                                                                                        |   | (30) |
| Accounts                    payable                                                                               |  (1,069)                                                                                     |   | 769 |
| Accrued                    liabilities and compensation                                                           |  (716)                                                                                       |   |   (5,998) |
| Net                    cash used in operating activities                                                          | (65,143)                                                                                          |   |  (69,205) |
|     Investing                    Activities:                                        |                                                                                              |   |   |
| Purchases                    of investments                                                                       | (585,205)                                                                                         |   | (290,184) |
| Maturities                    of investments                                                                      | 597,711                                                                                           |   | 315,170 |
| Purchases                    of property and equipment                                                            | (2,406)                                                                                           |   |  (9,984) |
| Net                    cash provided by  investing activities                                           | 10,100                                                                                            |   |  15,002 |
|     Financing                    Activities:                                                  |                                                                                              |   |   |
| Proceeds                    from issuance of debt, net of debt financing costs                                    |  82,257                                                                                      |   |                — |
| Net                    proceeds from exercise of stock options, warrants and                    other             | 6,404                                                                                             |   | 192 |
| Proceeds                    from release of security deposits associated with debt                                |  648                                                                                         |   |  501 |
| Issuance                    of common stock under the Employee Stock Purchase Plan                                | 589                                                                                               |   | 408 |
| Proceeds                    from equipment financing arrangement, net of debt financing                    costs  |                — |   |  7,624 |
| Payments                    on long-term debt                                                                     |  (3,923)                                                                                     |   |  (2,072) |
| Payments                    on capital lease obligations                                                          |  (851)                                                                                       |   |  (1,442) |
| Payments                    on facility lease obligation                                                          |  (95)                                                                                        |   |  (75) |
| Net                    cash  provided by financing activities                                           |  85,029                                                                                      |   |   5,136 |
| Net                    increase (decrease) in cash and cash equivalents                                           |  29,986                                                                                      |   |  (49,067) |
| Cash                    and cash equivalents at beginning of year                                                 | 60,964                                                                                            |   | 81,949 |
| Cash                    and cash equivalents at end of period                                                     | $        90,950                                           |   | $                          32,882 |
|                                                                                                              |                                                                                              |   |   |

----

**DENDREON          CORPORATION**

**NOTESTO          CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**1.          BUSINESS, PRINCIPLES OF CONSOLIDATION AND BASIS OF          PRESENTATION**

*Business*

*Principles          of Consolidation*

*Basis          of Presentation*

*Net          Loss Per Share*

----

**2.          SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Debt          Issuance Costs*

*Accounting          for Stock-Based Compensation*

|                                                       |                                            | **Employee                  Stock Options** |         | **Employee                  Stock Purchase Plan** |
|------------------------------------------------------------|-------------------------------------------------|---------------------------------------------|--------------|---------------------------------------------------|
| **For                  the Three Months Ended**            | **For                  the Three Months Ended** |
| **September                  30,**                         | **September                  30,**              |
|                                                       |                                       | **2007**                                    |         | **2006**                                          |   | **2007** |   | **2006** |
| Weighted                  average estimated fair value     |                                       | $5.61                                       |    | $3.02                                             |    | $2.14 |    | $1.79 |
|                                                       |                                            |                                        |         |                                              |   |   |   |   |
| **Weighted                  Average Assumptions**          |
|     Dividend                  yield(A) |                                       | 0.0%                                        |         | 0.0%                                              |   | 0.0% |   | 0.0% |
| Expected                  volatility(B)                    |                                       | 93%                                         |    | 81%                                               |    | 124% |    | 80% |
| Risk-free                  interest rate(C)                |                                       | 4.7%                                        |    | 4.6%                                              |    | 5.0% |    | 4.7% |
| Expected                  life(D)                          |                                       | 4.8                  years                  |    | 5.0                  years                        |    | 0.5                  years |    |  0.5                  years |

----

|                                                         |         | **Employee                    Stock Options**    |                                             | **Employee                    Stock Purchase Plan** |
|--------------------------------------------------------------|--------------|--------------------------------------------------|--------------------------------------------------|-----------------------------------------------------|
|                                                         |         | **For                    the Nine Months Ended** | **For                    the Nine Months Ended** |
|                                                         |         | **September                    30,**             | **September                    30,**             |
|                                                         |    | **2007**                                         |                                             | **2006**                                            |   | **2007** |   | **2006** |
| Weighted                    average estimated fair value     |    | $3.29                                            |                                        | $3.42                                               |    | $2.04 |    | $1.86 |
|                                                         |         |                                             |                                             |                                                |   |   |   |   |
| **Weighted                    Average Assumptions**          |
|     Dividend                    yield(A) |    | 0.0%                                             |                                             | 0.0%                                                |   | 0.0% |   | 0.0% |
| Expected                    volatility(B)                    |    | 80%                                              |                                        | 81%                                                 |    | 124% |    | 80% |
| Risk-free                    interest rate(C)                |    | 4.7%                                             |                                        | 4.6%                                                |    | 5.0% |    | 4.7% |
| Expected                    life(D)                          |    | 4.6                    years                     |                                        | 4.9                    years                        |    | 0.5                    years |    |  0.5                    years |

| (A) |   | We                    have not paid dividends on our common stock in the past and do                    not plan to                    pay any dividends in the near                    future. |
|-----|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B) |   | The                    expected stock price volatility is based on the historical volatility                    of                    our common stock. |
|-----|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C) |   |                       The risk-free interest rate is based on the implied yield available                    on                    U.S. Treasury zero-coupon issues with a term equal to the expected                    life of                    the award on the date of grant. |
|-----|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (D) |   |                       The expected life of the options represents the estimated period                    of time                    until exercise and is based on historical experience of similar                    awards,                    giving consideration to the                         contractual terms, vesting schedules and expectations of future                    employee                    behavior. The expected life of awards under the employee stock                    purchase                    plan represents the                       purchase period under the plan. |
|-----|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                 | **Shares**                        |   |   | **Weighted-Average**                      |   | **Weighted-Average**                    |   |                                       |
|------------------------------------------------------|-----------------------------------|--------|--------|-------------------------------------------|--------|-----------------------------------------|--------|--------------------------------------------|
|                                                 | **Subject                    to** |   |   | **Exercise                    Price per** |   | **Remaining**                           |   | **Aggregate                    Intrinsic** |
|                                                 | **Options**                       |   |   | **Share**                                 |   | **Contractual                    Life** |   | **Value**                                  |
| Outstanding,                    January 1, 2007 | 5,664,958                         |   |   | $7.48                                     |   |                                    |   |                                       |
|     Granted                      | 299,337                           |   |   |  5.04                                |   |                                    |   |                                       |
|     Exercised                    | (1,000,069)                       |   |   |  6.55                                |   |                                    |   |                                       |
|     Forfeited                    | (474,939)                         |   |   |                      6.97            |   |                                    |   |                                       |
| Outstanding,                    September 30, 2007   | 4,489,287                         |   |   | $7.57                                     |   | 6.76                                    |   | $6,913,973                                 |
| Exercisable,                    September 30, 2007   | 3,384,884                         |   |   | $8.40                                     |   | 6.14                                    |   | $3,853,067                                 |

*Restricted        Stock Awards*

----

|                                                                           | **2007**                                      |
|--------------------------------------------------------------------------------|-----------------------------------------------|
|                                                                           |                                          |   | **Weighted                  Average** |
|                                                                           | **Stock                  Awards**             |   | **Grant                  Date Fair Value** |
| Outstanding                  at beginning of period                            |      1,106,160       |   | $3.63 |
|     Granted                                                |     1,014,354             |   |                    6.00 |
|     Vested                                                 |     (483,389)             |   |                    4.47 |
|     Forfeited                  or                  expired |       (89,486)  |   |                    4.21 |
| Outstanding                  at end of period                                  |       1,547,639 |   |  $5.88 |

| **3.** | **RECENT                  ACCOUNTING                  PRONOUNCEMENTS** |
|--------|------------------------------------------------------------------------|

***New        Accounting Standards Not Yet Adopted***

----

| **4.** | **PROPERTY                  AND                  EQUIPMENT** |
|--------|--------------------------------------------------------------|

|                                                            | **September                  30,**                                                                                                                                                                                                               |   | **December 31,**                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ***(in                  thousands)***                           | **2007**                                                                                                                                                                                                                                         |   | **2006**                                                                                                                                                                                                                                                |
| Furniture                  and office equipment                 | $                                                                     1,252 |   | $                                                1,260                                            |
| Laboratory                  and manufacturing equipment         | 10,731                                                                                                                                                                                                                                           |   | 9,259                                                                                                                                                                                                                                                   |
| Computer                  equipment and software                | 9,496                                                                                                                                                                                                                                            |   | 9,308                                                                                                                                                                                                                                                   |
| Leasehold                  improvements                         | 15,676                                                                                                                                                                                                                                           |   | 4,526                                                                                                                                                                                                                                                   |
| Buildings                                                       |             1,730                                                                                                                                                                    |   |                                                        — |
| Construction                  in progress                       | 9,796                                                                                                                                                                                                                                            |   | 22,120                                                                                                                                                                                                                                                  |
|                                                            | 48,681                                                                                                                                                                                                                                           |   | 46,473                                                                                                                                                                                                                                                  |
| Less                  accumulated depreciation and amortization | (20,506)                                                                                                                                                                                                                                         |   | (15,943)                                                                                                                                                                                                                                                |
|                                                            | $                                                                   28,175            |   | $                                              30,530                                                       |

**5.           ACCRUED        LIABILITIES**

|                                         | **September                    30,**                                                                                                                                                                                       |   | **December 31,**                                                                                                                                                                                                                                                 |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ***(in                    thousands)***      | **2007**                                                                                                                                                                                                                   |   | **2006**                                                                                                                                                                                                                                                              |
| Clinical                    trial costs      | $                                                   2,161       |   | $                                                  2,699                                                        |
| Accrued                    Legal Fees        | 1,512                                                                                                                                                                                                                      |   | 249                                                                                                                                                                                                                                                                   |
| Accrued                    interest expense  |                 1,185                                                                                                                      |   |                                                            — |
| Deferred                    rent             |                    598                                                                                                      |   |                  667                                                                                                                                                             |
| Antigen                    manufacturing     |                    390                                                                                                      |   |                  350                                                                                                                                                             |
| Construction                    in progress  |                      71                                                                                           |   |                  210                                                                                                                                                             |
| Other                    accrued liabilities |                 1,430                                                                                                                      |   |               2,613                                                                                                                                                                             |
|                                         | $                                                    7,347 |   | $                                                    6,788                                            |

----

**6.            CONVERTIBLE        SENIOR NOTES**

----

**7.           COMMITMENTS          AND CONTINGENCIES**

*McGuire v. Dendreon            Corporation, et al.*
*McGuire, et al. v. Dendreon Corporation, et al.,*

----

*Loh v. Gold, et            al.*

**8.           COMPREHENSIVE          LOSS**

|                                                        | **Three                      months ended**                                                                                                                                             |   | **Nine                      months ended**                                                                                                                                          |
|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                        | **September                      30,**                                                                                                                                                  |   | **September                      30,**                                                                                                                                              |
| ***(in                      thousands)***                   | **2007**                                                                                                                                                                                |   | **2006**                                                                                                                                                                            |   | **2007** |   | **2006** |
| Net                      loss                               | $                             (19,230) |   | $                                                                 (20,743) |   | $                      (72,313) |   | $                      ( 70,155) |
| Net                      unrealized gain on securities |  51                                                                                                                                                                                |   |             242                                                                                                         |   |           65 |   |             201 |
| Comprehensive                      loss                     | $                             (19,179) |   | $                       (20,501)                                 |   | $                      (72,248) |   | $                                                                 (69,954) |

**9.            RESTRUCTURING**

| **Restructuring                      Charges (in thousands)**                                          |   | **Severance                      and outplacement costs**                                                                                                                                                                              |   | **Contract                      termination costs**                                                                                                                                                                                                   |   | **Stock                      compensation costs**                                                                                                                                                                                                |   | **Total**                                                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Balance                      as of March 31, 2007                                                      |   |  $                                  —             |   |  $                                  —                            |   |  $                                  —                       |   |  $                                                — |
|     Accrued                      in Second Quarter 2007                            |   |                                                       1,440            |   |                  300                                                                                                                                             |   |                  199                                                                                                                                        |   | 1,939                                                                                                                                                                                                                                                                                                          |
|     Payments                      made                      in Second Quarter 2007 |   |                                                    (1,118)                            |   |                                                           — |   | (199)                                                                                                                                                                                                                                            |   | (1,317)                                                                                                                                                                                                                                                                                                        |
|     Balance                      as of June 30, 2007                               |   |                                                          322 |   | 300                                                                                                                                                                                                                                                   |   |                  —                                                                                                                                    |   |     622                                                                                                                                                                                                                                                                                    |
|     Accrued                      in Third Quarter 2007                             |   |                                     191            |   |                  —                                                                                                                                         |   |                  —                                                                                                                                    |   |     191                                                                                                                                                                                                                                                                                    |
|     Payments                      made                      in Third Quarter 2007  |   |                                  (276)                            |   | (300)                                                                                                                                                                                                                                                 |   |                  —                                                                                                                                    |   |     (576)                                                                                                                                                                                                                                                                                  |
| Balance                      as of  September 30, 2007                                       |   | $                                  237                       |   | $                                                        —            |   | $                                                         — |   | $                                                                    237 |

**10.           SUBSEQUENT            EVENTS**

----

| **ITEM 2.** | **MANAGEMENT’SDISCUSSION                      AND ANALYSIS OF FINANCIAL CONDITION                      AND RESULTS OF OPERATIONS** |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------|

**OVERVIEW**

----

*Accounting          for Uncertainty in Income Taxes*

----

***New          Accounting Standards Not Yet Adopted***

**RESULTS          OF OPERATIONS FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30,          2007 AND          2006**

*Revenue*

*Research          and Development Expenses*

----

|                                                             | **Three months ended**                                                                                                                                                                                       |   | **Nine months ended**                                                                                                                                                                             |
|------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                             | **September                  30,**                                                                                                                                                                                     |   | **September                  30,**                                                                                                                                                                          |
|                                                             | **2007**                                                                                                                                                                                                               |   | **2006**                                                                                                                                                                                                    |   | **2007** |   | **2006** |
| Clinical                  programs:                              |                                                                                                                                                                                                                   |   |                                                                                                                                                                                                        |   |   |   |   |
|     Direct                  costs            | $                                                  3.2 |   | $                                                4.2  |   | $                                                19.8 |   | $                                22.4 |
|     Indirect                  costs          |   9.4                                                                                                                                                                                                        |   |           10.6                                                                                                                                            |   |  32.8 |   |           31.1 |
|     Total                  clinical programs |  12.6                                                                                                                                                                                                             |   |           14.8                                                                                                                                            |   |           52.6 |   |  53.5 |
|     Discovery                  research      |           0.8                                                                                                                                                        |   |           1.0                                                                                                                                             |   |           2.2 |   |           3.5 |
| Total                  research and development expense          | $                                                13.4            |   | $                                                15.8 |   | $                                                 54.8 |   | $                                                 57.0 |

*General          and Administrative Expenses*

*Interest          Income*

*Interest          Expense*

----

**LIQUIDITY          AND CAPITAL RESOURCES**

*Cash          Uses*

|   | **•** |   | costs                    for the development of marketing, manufacturing, information                    technology                    and other infrastructure and activities related to the commercialization                    of Provenge; |
|--------|-------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |        |   |                                                                                                                                                                                                                                            |
|   | **•** |   | working                    capital needs;                                                                                                                                                                                                       |
|   |        |   |                                                                                                                                                                                                                                            |
|   | **•** |   | costs                    associated with hiring additional specialized                    personnel;                                                                                                                                            |
|   |        |   |                                                                                                                                                                                                                                            |
|   | **•** |   | supporting                    clinical trials of Provenge and for our other products under                    development;                                                                                                                      |
|   |        |   |                                                                                                                                                                                                                                            |
|   | **•** |   | operating                    and expanding the Facility; and                                                                                                                                                                                    |
|   |        |   |                                                                                                                                                                                                                                            |
|   | **•** |   | continuing                    our internal research and development                    programs.                                                                                                                                                |

*Construction          and Facility Expenses*

----

*Production          and Supply Expenses*

*Financings          from the Sale of Securities*

----

| **Contractual                Commitments**                                |   | **Total** |    |   | **1 Year** |   | **2-3 Years** |    | **4-5 Years** |    | **Thereafter** |
|---------------------------------------------------------------------------|--------|-----------|---------|--------|-----------------|--------|--------------------|---------|--------------------|---------|----------------|
| Convertible                senior subordinated notes (including interest) | $      | 112,415   |    |   |  $         | 4,049  |               |  $ | 8,099              |    |  $        | 8,099 |   |  $ | 92,168 |
| Facility                lease obligation (including interest)             |   |      | 14,717  |   |            |   | 801                |    |               | 1,697   |           |   | 1,826 |   |   | 10,393 |
| Contractual                commitments                                    |   |      | 12,908  |   |            |   | 12,908             |    |               | — |           |   | — |   |   | — |
| Debt                obligations (including interest)                      |   |      | 10,142  |   |            |   | 6,345              |    |               | 3,797   |           |   | — |   |   | — |
| Operating                leases                                           |   |      | 16,543  |   |            |   | 3,205              |    |               | 6,731   |           |   | 4,204 |   |   | 2,403 |
| Capital                lease obligations (including interest)             |   |      | 1,238   |   |            |   | 1,029              |    |               | 209     |           |   | — |   |   | — |
| Unconditional                purchase obligations                         |   |      | 190     |   |            |   | 190                |    |               | — |           |   | — |   |   | — |
|                                                                      |   | $         | 168,153 |   |            | $      | 28,527             |    | $                  | 20,533  |           | $ | 14,129 |   | $ | 104,964 |

| **ITEM 3.** | ** QUANTITATIVE                   AND QUALITATIVE DISCLOSURES ABOUT MARKET                  RISK** |
|------------------|--------------------------------------------------------------------------------------------------------------|

----

**ITEM 4.                   CONTROLSAND        PROCEDURES**

**PART        II. OTHER INFORMATION**

| **ITEM 1.** | **LEGAL                  PROCEEDINGS** |
|------------------|----------------------------------------|

*McGuire v. Dendreon        Corporation, et al.*
*McGuire, et al. v. Dendreon Corporation, et al.,*

*Loh v. Gold, et        al.*

----

| **ITEM 5.** | **OTHER                  INFORMATION** |
|------------------|----------------------------------------|

----

| **ITEM 6.** | **EXHIBITS** |
|------------------|--------------|

**EXHIBIT          INDEX**

|                                                         |                                                                                                                                                                                                                                                                     |
|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Exhibit****Number**                              | **Description**                                                                                                                                                                                                                                                |
|   3.1                                    | Amended                      and Restated Certificate of Incorporation. (1)                                                                                                                                                                                              |
|                                                         |                                                                                                                                                                                                                                                                     |
|   3.2                                    | Certificate                      of Amendment to Amended and Restated Certificate of Incorporation.                      (2)                                                                                                                                             |
|                                                         |                                                                                                                                                                                                                                                                     |
|   3.3                                    | Amended                      and Restated Bylaws. (3)                                                                                                                                                                                                                    |
|                                                         |                                                                                                                                                                                                                                                                     |
| 3.4                                                          | Amendment                      Number One to Amended and Restated Bylaws, adopted November                      2,                      2007.                                                                                                                            |
|                                                         |                                                                                                                                                                                                                                                                     |
|   4.1                                    | Specimen                      Common Stock Certificate. (4)                                                                                                                                                                                                              |
|                                                         |                                                                                                                                                                                                                                                                     |
|   4.2                                    | Certificate                      of Designation of Series A Junior Participating Preferred Stock.                      (5)                                                                                                                                               |
|                                                         |                                                                                                                                                                                                                                                                     |
|   4.3                                    | Rights                      Agreement between the registrant and Mellon Investor Services                      LLC, as                      Rights Agent, dated September 18, 2002. (6)                                                                             |
|                                                         |                                                                                                                                                                                                                                                                     |
|   4.4                                    | Form                      of Right Certificate. (7)                                                                                                                                                                                                                      |
|                                                         |                                                                                                                                                                                                                                                                     |
| 10.1                                                         | Purchase                      Agreement, dated as of June 5, 2007, between Dendreon Corporation and                      Merrill Lynch, Pierce, Fenner & Smith Incorporated.                      (8)                                                           |
|                                                         |                                                                                                                                                                                                                                                                     |
|          10.2   | Indenture,                      dated as of June 11, 2007, between Dendreon Corporation and The Bank                      of New York Trust Company, N.A. (9)                                                                                                       |
|                                                         |                                                                                                                                                                                                                                                                     |
|          10.3   | Registration                      Rights Agreement, dated as of June 11, 2007 between Dendreon                      Corporation and Merrill Lynch, Pierce, Fenner & Smith Incorporated.                      (10)                                               |
|                                                         |                                                                                                                                                                                                                                                                     |
| 10.4                                                         | Third                      Amendment to Lease Agreement between Dendreon Corporation and                      ARE – 3005                      First Avenue, LLC. (11)                                                                                              |
|                                                         |                                                                                                                                                                                                                                                                     |
| 10.5                                                         | Amended                      and Restated 2000 Employee Stock Purchase Plan 2007 Offering.                      (12)                                                                                                                                                     |
|                                                         |                                                                                                                                                                                                                                                                     |
| 10.6                                                         | Common                      Stock Purchase Agreement, dated as of October 11, 2007 between                      Dendreon                      Corporation and Azimuth Opportunity, Inc. (13)                                                                             |
|                                                         |                                                                                                                                                                                                                                                                     |
|                        31.1                   | Certification                      of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley                      Act of 2002.                                                                                                                            |
|                                                         |                                                                                                                                                                                                                                                                     |
|                        31.2                   | Certification                      of Principal Financial Officer pursuant to Section 302 of the                      Sarbanes-Oxley Act of 2002.                                                                                                                        |
|                                                         |                                                                                                                                                                                                                                                                     |
|                        32      | Certification                      of Chief Executive Officer and Principal Financial Officer                      pursuant to 18                      U.S.C § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley                      Act of 2002. |

|                        (1) | Incorporated                      by reference to Exhibit 3.1 filed with the registrant’s Form 10-Q for the                      quarter ended March 31, 2002, File No.                      000-30681. |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        (3) | Incorporated                      by reference to Exhibit 3.2 filed with the registrant’s Form 10-Q for the                      quarter ended June 30, 2004, File No.                      000-30681. |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        (4) | Incorporated                      by reference to Exhibit 4.1 filed with the registrant’s Registration                      Statement on Form S-1/A, File                      No. 333-31920. |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        (5) | Incorporated                      by reference to Exhibit 4.1 filed with the registrant’s Registration Form                      8-K, filed with the SEC on September 25, 2002, File No.                      000-30681. |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   (6) | Incorporated                      by reference to Exhibit 99.2 filed with the registrant’s Registration Form                      8-K, filed with the SEC on September 25, 2002, File No.                      000-30681. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        (7) | Incorporated                      by reference to Exhibit 99.3 filed with the registrant’s Form 8-K, filed                      with the SEC on September 25, 2002, File No.                      000-30681. |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        (8) | Incorporated                      by reference to Exhibit 10.1 filed with the registrant’s Form 8-K, filed                      with the SEC on June 6, 2007, File No.                      000-30681 |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        (9) | Incorporated                      by reference to Exhibit 10.1 filed with the registrant’s Form 8-K, filed                      with the SEC on June 12, 2007, File No.                      000-30681. |
|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        (10) | Incorporated                      by reference to Exhibit 10.2 filed with the registrant’s Form 8-K, filed                      with the SEC on June 12, 2007, File No.                      000-30681. |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  (11)                       Incorporated by reference to Exhibit 10.1 filed with the registrant’s Form                      8-K, filed with the SEC on August 23, 2007, File No.                      000-30681. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  (12)                       Incorporated by reference to Exhibit 10.2 filed with the registrant’s Form                      8-K, filed with the SEC on August 23, 2007, File No.                      000-30681. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  (13)                       Incorporated by reference to Exhibit 10.1 filed with the registrant’s Form                      8-K, filed with the SEC on October 12, 2007, File No.                      000-30681. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**SIGNATURES**

|   | Date:                    November 7, 2007 |
|--------|------------------------------------------------|

|  **DENDREON                    CORPORATION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                             By:      | /s/                    MITCHELL H. GOLD, M.D. |
| **Mitchell                    H. Gold, M.D.**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | **President                    and Chief Executive Officer** |
|                                                                                                                             By: | /s/                    GREGORY T. SCHIFFMAN |
| **Gregory                    T. Schiffman**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | **Senior                    Vice President, Chief Financial Officer and Treasurer (Principal                    Financial                    Officer)** |
|                                                                                                                             By: | /s/                    GREGORY R. COX |
| **Gregory                    R. Cox**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | **(Principal                    Accounting Officer)** |

----

**EXHIBIT            INDEX**

|                                                                               |                                                                                                                                                                                                                                                                             |
|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Exhibit****Number**                                                    | **Description**                                                                                                                                                                                                                                                             |
|   3.1                                                          | Amended                        and Restated Certificate of Incorporation. (1)                                                                                                                                                                                                    |
|                                                                               |                                                                                                                                                                                                                                                                             |
|   3.2                                                          | Certificate                        of Amendment to Amended and Restated Certificate of Incorporation.                        (2)                                                                                                                                                 |
|                                                                               |                                                                                                                                                                                                                                                                             |
|   3.3                                                          | Amended                        and Restated Bylaws. (3)                                                                                                                                                                                                                          |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 3.4                                                                                | Amendment                        Number One to Amended and Restated Bylaws, adopted November                        2,                        2007                                                                                                                               |
|                                                                               |                                                                                                                                                                                                                                                                             |
|   4.1                                                          | Specimen                        Common Stock Certificate. (4)                                                                                                                                                                                                                    |
|                                                                               |                                                                                                                                                                                                                                                                             |
|   4.2                                                          | Certificate                        of Designation of Series A Junior Participating Preferred                        Stock.                        (5)                                                                                                                            |
|                                                                               |                                                                                                                                                                                                                                                                             |
|   4.3                                                          | Rights                        Agreement between the registrant and Mellon Investor Services                        LLC, as                        Rights Agent, dated September 18, 2002. (6)                                                                               |
|                                                                               |                                                                                                                                                                                                                                                                             |
|   4.4                                                          | Form                        of Right Certificate. (7)                                                                                                                                                                                                                            |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 10.1                                                                               | Purchase                        Agreement, dated as of June 5, 2007, between Dendreon Corporation and                        Merrill Lynch, Pierce, Fenner & Smith Incorporated.                        (8)                                                             |
|                                                                               |                                                                                                                                                                                                                                                                             |
|                                  10.2 | Indenture,                        dated as of June 11, 2007, between Dendreon Corporation and The Bank                        of New York Trust Company, N.A. (9)                                                                                                           |
|                                                                               |                                                                                                                                                                                                                                                                             |
|                                  10.3 | Registration                        Rights Agreement, dated as of June 11, 2007 between Dendreon                        Corporation and Merrill Lynch, Pierce, Fenner & Smith Incorporated.                        (10)                                                 |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 10.4                                                                               | Third                        Amendment to Lease Agreement between Dendreon Corporation                        and ARE – 3005                        First Avenue, LLC. (11)                                                                                                |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 10.5                                                                               | Amended                        and Restated 2000 Employee Stock Purchase Plan 2007 Offering.                        (12)                                                                                                                                                         |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 10.6                                                                               | Common                        Stock Purchase Agreement, dated as of October 11, 2007 between                        Dendreon                        Corporation and Azimuth Opportunity, Inc. (13)                                                                               |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 31.1                                                                     | Certification                        of Chief Executive Officer pursuant to Section 302 of the                        Sarbanes-Oxley                        Act of 2002.                                                                                                         |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 31.2                                                                     | Certification                        of Principal Financial Officer pursuant to Section 302 of                        the                        Sarbanes-Oxley Act of 2002.                                                                                                     |
|                                                                               |                                                                                                                                                                                                                                                                             |
| 32                                                        | Certification                        of Chief Executive Officer and Principal Financial Officer                        pursuant to 18                        U.S.C § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley                        Act of 2002. |

|                          (1) | Incorporated                        by reference to Exhibit 3.1 filed with the registrant’s Form 10-Q for the                        quarter ended March 31, 2002, File No.                        000-30681. |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (3) | Incorporated                        by reference to Exhibit 3.2 filed with the registrant’s Form 10-Q for the                        quarter ended June 30, 2004, File No.                        000-30681. |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (4) | Incorporated                        by reference to Exhibit 4.1 filed with the registrant’s Registration                        Statement on Form S-1/A, File                        No. 333-31920. |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (5) | Incorporated                        by reference to Exhibit 4.1 filed with the registrant’s Registration Form                        8-K, filed with the SEC on September 25, 2002, File No.                        000-30681. |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (6) | Incorporated                        by reference to Exhibit 99.2 filed with the registrant’s Registration Form                        8-K, filed with the SEC on September 25, 2002, File No.                        000-30681. |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (7) | Incorporated                        by reference to Exhibit 99.3 filed with the registrant’s Form 8-K, filed                        with the SEC on September 25, 2002, File No.                        000-30681. |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (8) | Incorporated                        by reference to Exhibit 10.1 filed with the registrant’s Form 8-K, filed                        with the SEC on June 6, 2007, File No.                        000-30681 |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (9) | Incorporated                        by reference to Exhibit 10.1 filed with the registrant’s Form 8-K, filed                        with the SEC on June 12, 2007, File No.                        000-30681. |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          (10)   | Incorporated                        by reference to Exhibit 10.2 filed with the registrant’s Form 8-K, filed                        with the SEC on June 12, 2007, File No.                        000-30681. |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  (11)                         Incorporated by reference to Exhibit 10.1 filed with the                        registrant’s Form                        8-K, filed with the SEC on August 23, 2007, File No.                        000-30681. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  (12)                         Incorporated by reference to Exhibit 10.2 filed with the                        registrant’s Form                        8-K, filed with the SEC on August 23, 2007, File No.                        000-30681. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  (13)  Incorporated                        by reference to Exhibit 10.1 filed with the registrant’s Form 8-K, filed                        with the SEC on October 12, 2007, File No.                        000-30681. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----